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(n=584) and as obese if their relative weight was 2120 (n= 1024). There were 688 subjects with hypertension at study entry (systolic blood pressure >160, diastolic blood pressure >95, or treated). The 29-year relative risk (RR) of mortality from ischemic heart disease (IHD) or cardiovascular disease (CVD) associated with systolic blood pressure level was significant for both lean and obese subjects. Among hypertensive subjects, the RR of fatal IHD for lean versus obese hypertensive subjects was 1.87 (95% confidence interval, 1.21 to 2.88) and the RR of fatal CVD was 1.56 (95% confidence interval, Apositive association between obesity or body weight and hypertension has been well established.1-3 Longitudinal studies have shown that weight gain is associated with a higher probability of becoming hypertensive. [4] [5] [6] In addition, weight reduction among overweight hypertensive subjects usually results in a lowering of blood pressure. 7 Hypertension itself is an established potent risk factor for cardiovascular disease.8 Although the impact of hypertension and obesity on cardiovascular disease (CVD) is a commonly accepted tenet, the independent role of obesity as a cause of a CVD event is more controversial.9-11 Furthermore, several prospective studies have reported excess ischemic heart disease (IHD) or CVD mortality among lean hypertensive subjects.12-'6 This has led to considerable discussion regarding the relation between hypertension, body size, and cardiovascular disease. '7-22 Because the Tecumseh Community Health Study helped to establish current concepts regarding hypertension, obesity, and cardiovascular disease,5 '6,8,23 it was our aim to use the same data to reexamine the question of whether lean hypertensive subjects, both male and 1.10 to 2.20) using a Cox proportional-hazards model to adjust for the independent effects of age and traditional CVD risk factors. The findings are consistent with other studies in men showing lean hypertensive subjects to be at greater risk of IHD or CVD mortality than obese hypertensive subjects. A similar finding is now observed in women.
Conclusions Associations do not prove causality or dictate management. Nevertheless, the unexplained higher mortality in lean versus obese hypertensive subjects has now been reported with sufficient frequency to suggest that the association is real (if unexplained). Determining the reasons for this association may improve targeted prevention and treatment strategies. (Circulation. 1994; 89:703-711.) Key Words * follow-up studies * hypertension * obesity female, are at greater risk of fatal cardiovascular disease than obese hypertensive subjects.
Methods
The Tecumseh Study is a longitudinal investigation being conducted in a geographically defined area consisting of the midwestern town of Tecumseh, Michigan, and the rural area surrounding it. 24 The present analyses were restricted to individuals, ages 40 to 79 years at entry, who were without evidence of coronary heart disease as determined by ECG findings or physician diagnosis at entry examination.33 Data were available from a study of the prevalence of cancer in the Tecumseh cohort that allowed the determination of subjects with pathologically confirmed cancers. Those subjects with cancer diagnosed before entry or within 2 years after entry were excluded from these analyses. Although there were 887 hypertensive subjects in the Tecumseh cohort, 171 were excluded from these analyses because of existing coronary heart disease at entry to the study, and 16 were excluded because they had pathologically diagnosed cancer. In addition, 4 subjects were excluded because of missing heights or weights, and 8 were lost to follow-up, leaving 688 hypertensive subjects for study.
Prevalence and mortality rates were adjusted for age using the direct method of age adjustment and eight 5-year age categories.34 Confidence intervals (CIs) for mortality rates were calculated assuming that the variance of the standardized rate is the sum of the weighted variances in each age category. 35 The significance of differences in proportions for categorical variables was determined by X2 analyses with adjustments for age carried out by the Mantel-Haenszel method.36 Means of continuous variables were adjusted for age using ANCOVA. 37 The Cox proportional hazards model was used to analyze survival data for which the time to all-cause mortality, cardiovascular mortality, or IHD mortality might have been influenced by a set of one or more risk factors or covariates.3839 Adjustments for smoking included both the current number of cigarettes smoked per day and a variable for smoking status (ever, never). Models that included adjustment for drinking also used variables for both drinking status (ever, never) and amounts consumed. Use of this multivariate technique allowed the independent relative risk (RR) associated with a prognostic variable to be evaluated while simultaneously adjusting for other baseline characteristics using progressively censored data. Length of follow-up for each subject was calculated by subtracting a subject's date of entry into the study from their date of last contact, if they were alive at follow-up, or from their date of death.
Results

Total Population
A total of 2181 men and women, aged 40 to 79 years, were free of both coronary disease and cancer at entry between 1959 and 1965; 32% were hypertensive. During the 29-year follow-up period, from entry through 1987, there were 455 deaths among persons classified as hypertensive at baseline. These 455 deaths included 151 IHD deaths, 105 additional CVD deaths, and 199 non-CVD deaths. Table 1 shows the RRs of IHD for age, sex, and systolic blood pressure in three relative weight categories, simultaneously adjusted for serum cholesterol, cigarette smoking status, atypical glucose tolerance, and use of antihypertensive medication. In these models, systolic blood pressure was a significant independent predictor of IHD death for all subjects, whether lean, intermediate weight, or obese.
The Figure compares the age-adjusted CVD mortality rates of the 688 hypertensive subjects with the remainder of the cohort, plotted by decile of MRW. Those with hypertension had higher CVD mortality Metropolitan Relative Weight Decile
Graph of age-adjusted 29-year cardiovascular disease (CVD) mortality by decile of Metropolitan relative weight and hypertension status.
rates than normotensive subjects over the entire range of relative weight. The distance between the two curves is wider at lower levels of MRW and narrows by the sixth decile, suggesting a higher RR in lean hypertensive subjects than among obese hypertensive subjects. A similar pattern was observed for IHD deaths (data not shown).
Hypertensive Subgroup Because our primary aim was to evaluate the association of relative weight with outcome among hypertensive subjects, the remainder of the analyses were restricted to the 688 men and women with hypertension. Table 2 shows the age-adjusted prevalence of selected cardiovascular risk factors among these hypertensive subjects over categories of relative weight. A significantly greater percentage of lean hypertensive subjects was male (61.9%) compared with obese hypertensive subjects (34.9%). Lean hypertensive subjects were more often current smokers at baseline (55.7%) than obese hypertensive subjects (27.9%). Lean subjects were more often current drinkers (68.1%) than obese hypertensive subjects (47.8%). Although not statistically significant, lean hypertensive subjects more often had ECG evidence of left ventricular hypertrophy (7.1%) than was exhibited by obese hypertensive subjects (4.4%). However, a greater percentage of obese hypertensive subjects had atypical glucose tolerance (14.9% versus 10.2%) and were taking antihypertensive medication compared with lean hypertensive subjects (16.4% versus 11.5%), although neither difference was statistically significant. Table 3 shows a comparison of the age-adjusted means of selected cardiovascular risk factors measured as continuous variables by categories of MRW. A statistical comparison of the mean values for lean hypertensive versus obese hypertensive subjects found significant differences between the two categories for all examined risk variables except serum cholesterol and mean per-week ethanol consumption among current drinkers. Lean hypertensive subjects were older and had significantly lower blood pressures than subjects who were obese. They also had significantly smaller skinfolds, lower ratios of subscapular-to-triceps skinfolds, and they smoked more. Among the subset with postchallenge blood glucose levels, lean hypertensive subjects also had significantly lower blood glucose levels. Sex-specific analyses were also conducted in an attempt to determine whether the pattern of excess risk of CVD or IHD mortality among lean hypertensive subjects was consistent for each sex. For women, the results were statistically significant and the RRs were similar in the group as a whole (Table 5 ). For men, the pattern of excess risk was similar although the RRs were lower and reached statistical significance at the a=0.05 level for the IHD end point only.
Because tobacco use is undoubtedly an important confounder in the association between CVD mortality and hypertension in lean subjects, separate analyses were repeated for smokers and nonsmokers (Table 6 ). We found that among male hypertensive smokers, the RR of IHD mortality associated with being < 10% over ideal weight versus being .20% over ideal weight was 2.58 (95% CI, 1.07 to 6.24). There was also a significant excess risk for lean versus obese female hypertensive smokers. Among nonsmokers (never-smokers and exsmokers) the RR for CVD mortality associated with being lean compared with being obese was significant for both sexes combined. However, in sex-specific analyses, although the RRs were greater than one, they achieved statistical significance only for CVD mortality among women. The 13 lean hypertensive men who had never smoked represent 4.3% of the hypertensive men and 6.7% of the CVD deaths in that group. The 28 lean hypertensive women who had never smoked represent 7.2% of hypertensive women and 9.7% of the CVD deaths. The small numbers of lean male never-smokers resulted in unstable mortality rates and precluded anal- 
Discussion
Consistent with other studies, we found that elevated blood pressure was associated with increased risk for CVD and IHD mortality in both obese and lean subjects, even after adjustment for confounders including smoking. Although this evidence continues to support the concept that elevated blood pressure is detrimental to health, the joint relation between body size and blood pressure on mortality experience remains controversial.
We observed that the relation between our measure of obesity and IHD or CVD mortality was not linear over the entire range of blood pressure. Indeed, we observed excess risk of mortality among lean hypertensive compared with obese hypertensive subjects. Graphic representations of measures of body mass and IHD or CVD mortality for several other cohort populations indicate, at least for hypertensive subjects, that the relation of body size and IHD or CVD mortality is not linear.12 '14'17,20 It has been argued that failure to find a significant nonzero interaction between blood pressure and body size over the entire range of blood pressure must lead to the conclusion that lean hypertensive subjects are not at higher risk than those who are obese. '7 We did fail to find a significant interaction between blood pressure and MRW for either IHD or CVD mortality when we assumed a linear relation over the entire blood pressure range. However, when we assumed a U-shaped or parabolic relation, we were able to demonstrate a significant interaction between body size and blood pressure for IHD mortality, although not for the more inclusive end point of all CVD mortality. If death rates from IHD or CVD for normotensive subjects increase with body size, findings for models that make no distinction between hypertensive and normotensive subjects may be distorted. 16 A clearer picture emerged in examining data from hypertensive subjects alone that supported the contention that lean hypertensive men and women are at greater risk of cardiovascular mortality than those who are obese. Issues that may confound these results include the distribution of smoking and alcohol use in the population and the presence of preexisting disease.
The role of smoking in the excess risk of lean hypertensive subjects for CVD mortality is of substantial interest, particularly because smoking is a risk factor that can be altered. Survival analyses, which adjusted for both smoking status and the number of cigarettes currently smoked per day, resulted in significant RR ratios for lean hypertensive subjects despite the adjustments for baseline smoking. When we examined the body size-mortality relation among current smokers, we found that the excess mortality for lean hypertensive subjects persisted. Analyses among nonsmokers also provided evidence for the excess risk. These nonsmokers do include past smokers whose risk may well be more like that of current smokers than never-smokers. Unfortunately, our ability to investigate whether this relation remains consistent among never-smokers is hampered by small numbers. Whereas the excess risk persisted among female never-smokers, numbers were too small to evaluate the RR for men. At the baseline Tecumseh examinations, which predated present antismoking advice, only 23% of male hypertensive subjects were never-smokers, and only 4.3% of male hypertensives were lean never-smokers.
Data from the Hypertension Detection and Follow-up Program (HDFP) also have been used to examine the mortality experience of hypertensive subjects across classes of body mass. 16 They reported excess total mortality among lean hypertensive subjects, including excess CVD mortality among lean hypertensive men. However, they indicated that this excess mortality was most notable for non-CVD deaths. In the Tecumseh cohort, the excess RR of mortality from all causes for lean versus obese hypertensive subjects was not significantly elevated, in contrast to the stronger significant increased risk for IHD mortality. Moreover, for non-CVD mortality, the relation was inconsistent between the sexes. Whereas being lean was associated with a significantly reduced risk for non-CVD mortality in men, this was not true for women. The failure of these non-CVD models to achieve significance for both sexes could be a function of lack of statistical power caused by the relatively small number of non-CVD events in this study. Likewise, the lack of consistency between the sexes could be a function of the levels of other contributing risk factors.
Evidence from the HDFP study implicates alcohol and smoking as contributing factors to excess risk among lean hypertensive subjects because of excess neoplastic or respiratory deaths, observed among lean hypertensive subjects who smoked, and excess cirrhotic and violent deaths. Whereas there was a significant difference in smoking behavior between lean and obese hypertensive subjects in Tecumseh, the percentage of current smokers and the amount they smoked was lower than in the HDFP study. Furthermore, there was no significant difference in mean age-adjusted weekly ethanol consumption between lean and obese hypertensive subjects for either sex. Heavy drinking was not common among these hypertensive subjects: 87% drank less than one drink per day, only 1.2% consumed more than two subjects, there were no cirrhotic deaths, and the two death certificates that mentioned cirrhosis as being present were for obese subjects. Furthermore, with only 16 violent deaths among hypertensive subjects, no excess risk for violent death could be demonstrated among lean hypertensive subjects in this cohort. Levels of deleterious lifestyle activities may not have been high enough among lean hypertensive subjects in Tecumseh to cause an excess in non-CVD mortality. Despite this situation, excess IHD and CVD mortality persist in this group.
Clearly, there are differences between the Tecumseh and HDFP cohorts. The Tecumseh cohort was drawn from a white midwestern farming community. The participants in these analyses were born between 1879 and 1924 and had been followed for up to 29 years. Subjects with known cancer or coronary heart disease at baseline were excluded from these analyses. The HDFP cohort was drawn from a cross section of communities and was designed to include urban and lower socioeconomic groups. Participants in the HDFP cohort, which included 44% blacks, were born between 1904 and 1943 and were followed for 8.3 years. Subjects were included regardless of baseline cancer or coronary disease status. Although these two cohorts may have diverged on many parameters, including alcohol intake, smoking habits, and distribution of body size, it is more remarkable that, despite these differences, both studies have provided evidence that there is a significant health risk for lean hypertensive subjects.
It would be reasonable to postulate that the disadvantage for lean hypertensive subjects is due to preexisting disease. For this reason, we excluded from the cohort all subjects with coronary heart disease or cancer at entry. Also, in analyses not presented, we removed all people who died within 5 years after entry. Removal of these early deaths did not change the significance or the pattern of risk.
It has been hypothesized that lean hypertensive subjects may suffer from higher peripheral vascular resistance than those who are obese. Messerli18 suggested that lower vascular resistance associated with an increase in body size could well serve as the pathophysiological mechanism by which obesity exerts a protective effect on certain vascular beds and ultimately decreases the risk of both coronary artery and peripheral vascular disease. Unfortunately, early Tecumseh data do not allow direct measurement of vascular resistance, cardiac output, or kidney function and therefore cannot be used to examine this theory.
In an effort to test the hypothesis that lean hypertensive subjects have suffered end-organ damage,14 we examined ECG evidence of left ventricular hypertrophy. In this cohort, the prevalence of left ventricular hypertrophy was disproportionately high among lean hypertensive subjects at As with any longitudinal study, there are problems in trying to predict mortality using baseline risk factors that do not stay static over the length of the follow-up period. Changes in smoking habits, blood pressure body weight all could have an influence on the mortality of these hypertensive subjects. The Tecumseh cohort has experienced a reduction in smoking and changes in treatment patterns for hypertension that parallel changes experienced throughout the United States during the last three decades. At baseline in 1959, 56% of the lean and 28% of the obese hypertensive subjects were current smokers. By 1978, the percentage of smokers had dropped to 32% of the lean and 16% of the obese. Although these smoking habit changes could have an effect on the differential mortality rates between lean and obese smokers, they do not explain why lean female never-smokers also experienced excess mortality in comparison with obese female never-smokers. Changes in treatment for hypertension may be more relevant. At baseline, only 10% to 15% of hypertensive subjects were treated with medication, and the medications used were often not effective. The difference in the proportion of lean versus obese subjects treated with antihypertensives was not statistically significant. However, by the end of the second decade of follow-up, treatment was much more widespread, and drugs were more efficacious. Information from a 1978 survey of the community shows that while the proportion of lean hypertensive subjects receiving antihypertensive therapy had risen to 47%, the proportion of obese subjects receiving similar therapy had risen to nearly 70%. It is reasonable to speculate that obese hypertensive subjects in this cohort were more likely to be placed under effective blood pressure control and more rigorously encouraged to quit smoking than their lean counterparts.
We have shown that lean hypertensive subjects, men and women, are at significantly higher risk for CVD mortality than obese hypertensive subjects. This excess risk was not eliminated by adjustments for age, sex, smoking status and cigarettes, serum cholesterol, atypical glucose parameters, use of antihypertensive medication, or the presence of preexisting left ventricular hypertrophy, coronary disease, or cancer. Other factors such as insulin resistance, central fat distribution, arrythmias, kidney disease, or lack of appropriate treatment may provide clues to the cause of this excess risk. Unfortunately, the relatively small numbers of causespecific deaths in each sex/weight/smoking group restrict the statistical power of this study to identify additional characteristics that are associated with this excess risk among lean hypertensive subjects. Further research may help to clarify whether hypertension in lean individuals is a distinct disease with strong genetic determinants or whether differences in outcome reflect increased vascular resistance.
The health risk to overweight individuals with hypertension is well documented. Being overweight is a risk factor for hypertension; hypertension, at any weight, is a significant risk factor for CVD mortality. Our results are consistent with this statement and should not be misinterpreted. These results do not suggest any diminution of the apparently causal role of obesity in hypertension. Furthermore, they do not imply that there should be any relaxation in the treatment of obese hypertensive individuals, whether that treatment is weight loss, dietary change, medication, or other therapy. However, the standard weight-loss advice given to 
